Effect of HIgh-flow Therapy in Long-term Oxygen Therapy (HILOT): A Multicenter, Registry-based, Randomized Clinical Trial
Status: Recruiting
Location: See all (2) locations...
Intervention Type: Other, Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
This is a registry-based, randomized, controlled clinical trial of the effect of added high-flow oxygen therapy (using the device Lumis HFT) during one year in people with long-term oxygen therapy (LTOT) for chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD).
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Age 40 years or older
• Ongoing LTOT: prescribed for at least 15 hours per day; and since at least 28 days as registered in Swedevox
• COPD or ILD as main underlying reason for LTOT
• Oxygen concentrator as stationary oxygen source in the home including night-time
• Body mass index (BMI) \< 35 kg/m2
Locations
Other Locations
Sweden
Research Unit, Blekinge University of Technology
RECRUITING
Karlskrona
Department of Heart, Lung and Clinical Physiology, Örebro University Hospital
RECRUITING
Örebro
Contact Information
Primary
Magnus Ekström, MD, PhD
magnus.ekstrom@med.lu.se
0455731000
Time Frame
Start Date: 2024-06-10
Estimated Completion Date: 2028-12
Participants
Target number of participants: 310
Treatments
Experimental: High-flow oxygen therapy
Intervention arm
Active_comparator: Low-flow oxygen therapy
Comparison arm
Related Therapeutic Areas
Sponsors
Leads: Skane University Hospital
Collaborators: Uppsala University Hospital, Vastra Gotaland Region, Blekinge Institute of Technology, Region Östergötland, Lund University, Swedish Heart Lung Foundation, The Swedish Research Council, Region Örebro County, Region Stockholm, Landstinget i Värmland, Region Västerbotten, Blekinge County Council Hospital, ResMed